Physician profile
Mita S Deoras
NPI 1942445770
$578.24
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $23.00 · 2021: $80.34 · 2022: $125 · 2023: $41.93 · 2024: $47.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $271.02 | 2019-2022 | |
| Ucb, INC. | $61.45 | 2019-2021 | |
| Abbvie INC. | $54.56 | 2021-2023 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $26.64 | 2020-2021 | |
| Averitas Pharma INC. | $24.80 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $22.45 | 2024 | Nourianz |
| Itamar Medical INC | $19.18 | 2023 | Watchpatone |
| Mylan Specialty L.P. | $17.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.35 | 2019 | |
| Portola Pharmaceuticals, LLC | $16.80 | 2019 | |
| Ge Healthcare | $16.61 | 2020-2021 | |
| Glaxosmithkline, LLC. | $15.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mita Deoras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.